Megestrol Acetate Shows Dual Benefits in ER-Positive Breast Cancer Treatment
Key Insights
The PIONEER trial demonstrates that adding low-dose megestrol acetate to standard anti-estrogen therapy significantly reduces tumor growth rates in ER-positive breast cancer (search) patients within two weeks of treatment.
Both 40mg and 160mg daily doses of megestrol acetate showed comparable anti-cancer effects when combined with letrozole, suggesting the lower dose provides therapeutic benefit with fewer side effects.
The synthetic progesterone mimic addresses a dual clinical need by simultaneously slowing tumor progression and managing troublesome hot flushes that often lead patients to discontinue anti-estrogen therapy.
A synthetic hormone that mimics progesterone has demonstrated significant anti-cancer activity when combined with standard anti-estrogen therapy for women with ER-positive breast cancer (search), according to results from the Cambridge-led PIONEER trial published in Nature Cancer.
The study found that megestrol acetate, already used to manage hot flushes in breast cancer (search) patients, can directly slow tumor growth when added to conventional treatment. This dual benefit addresses a critical clinical challenge: helping patients tolerate long-term anti-estrogen therapy while potentially improving treatment outcomes.
Clinical Trial Results Show Promising Efficacy
The PIONEER trial enrolled 198 post-menopausal women with ER-positive breast cancer (search) across ten UK hospitals, including Addenbrooke's Hospital in Cambridge. Patients were randomized into three groups: letrozole alone, letrozole plus 40mg daily megestrol acetate, or letrozole plus 160mg daily megestrol acetate.
In this "window of opportunity" trial, treatment was administered for two weeks prior to surgery. The percentage of actively growing tumor cells was assessed at baseline and again before surgery to measure treatment effects.
Results showed that adding megestrol acetate boosted letrozole's ability to block tumor growth, with comparable effects observed at both the 40mg and 160mg doses. Patients receiving the combination therapy experienced a greater decrease in tumor growth rates compared to those treated with anti-estrogen therapy alone.
"In the two-week window that we looked at, adding a progestin made the anti-estrogen treatment more effective at slowing tumor growth," said Dr. Rebecca Burrell, joint first author from the Cancer Research UK Cambridge Institute (search). "What was particularly pleasing to see was that even the lower dose had the desired effect."
Mechanistic Understanding from Laboratory Studies
Supporting the clinical findings, laboratory research by Professor Jason Carroll and colleagues at the Cancer Research UK Cambridge Institute (search) provided mechanistic insights into how progesterone affects ER-positive breast cancer (search) cells.
Using cell cultures and mouse models, the researchers demonstrated that progesterone stops ER-positive cancer cells from dividing by indirectly blocking the estrogen receptor (search), resulting in slower tumor growth. When mice treated with anti-estrogen hormone therapy also received progesterone, tumors grew even more slowly than with anti-estrogen treatment alone.
"These were very promising lab-based results, but we needed to show that this was also the case in patients," said Professor Carroll, who co-leads the Precision Breast Cancer (search) Institute.
Addressing Treatment Adherence Challenges
Around three-quarters of all breast cancers are ER-positive, meaning the tumors contain abundant estrogen receptors and rely on circulating estrogen for growth. While anti-estrogen medications effectively deprive cancer cells of estrogen, they can trigger menopause-like symptoms including hot flushes, joint and muscle pain, and potential bone loss.
These side effects can significantly impact quality of life and may lead some patients to discontinue treatment. Dr. Richard Baird from the Department of Oncology at the University of Cambridge, who led the PIONEER trial, explained the clinical significance: "If you're taking something long term, even seemingly relatively minor side effects can have a big impact."
Previous trials have already established that low-dose megestrol acetate effectively treats hot flushes in patients receiving anti-estrogen therapy. The current findings suggest this approach could reduce the likelihood of patients stopping their medication while simultaneously providing direct anti-cancer benefits.
Safety Profile and Dosing Considerations
The trial's findings are particularly significant because they demonstrate that the lower 40mg dose of megestrol acetate provides comparable anti-cancer effects to the higher 160mg dose. While the higher dose is licensed as an anti-cancer treatment, long-term use can cause side effects including weight gain and high blood pressure.
"Just a quarter of the dose was as effective, and this would come with fewer side effects," noted Dr. Burrell. The lower dose approach could make long-term treatment more tolerable while maintaining therapeutic efficacy.
Cost-Effective Treatment Option
Megestrol acetate's off-patent status makes it a potentially cost-effective addition to breast cancer (search) treatment protocols. This accessibility could benefit a broad patient population, particularly important given that ER-positive breast cancer (search) represents approximately 75% of all breast cancer cases.
Future Research Directions
While the PIONEER trial provides compelling evidence for megestrol acetate's dual benefits, researchers acknowledge that longer-term studies are needed to confirm sustained efficacy and safety. The trial only assessed effects over a two-week period, and follow-up studies will be required to determine whether the drug maintains its beneficial effects with reduced side effects over extended treatment periods.
The Cambridge team plans to expand research to larger patient cohorts and longer treatment durations to further evaluate the benefits and safety profile of megestrol acetate in combination with anti-estrogen therapies.
The research was funded by Anticancer Fund, with additional support from Cancer Research UK, Addenbrooke's Charitable Trust, and the National Institute for Health and Care Research Cambridge Biomedical Research Centre.